Table 1.
Demographic and clinical data of the sample (n=150)
| Characteristic | Value |
|---|---|
| Sex | |
| Male | 59 (39.3) |
| Female | 91 (60.7) |
| Age (yr), mean ± SD (range) | 43.3 ± 11.5 (18–65) |
| Education (yr) | 13 (0–18) |
| EDSS | 3.5 (0–7.5) |
| Ambulation status | |
| Fully ambulatory | 101 (67) |
| Ambulation restriction | 49 (33) |
| Disease duration (yr) | 10.5 (0–40) |
| Annualized relapse rate | 0.37 (0–2) |
| Disease course | |
| Relapsing-remitting | 108 (72) |
| Secondary-progressive | 36 (24) |
| Primary-progressive | 4 (6) |
| Disease-modifying treatment | |
| No treatment | 1 (0.7) |
| Interferon beta | 21 (14) |
| Glatiramer acetate | 5 (3.3) |
| Dimethyl fumarate | 13 (8.7) |
| Fingolimod | 15 (10) |
| Cladribine | 1 (0.7) |
| Natalizumab | 38 (25.3) |
| Teriflunomide | 6 (4) |
| Alemtuzumab | 19 (12.7) |
| Ocrelizumab | 22 (14.7) |
| Rituximab | 7 (4.7) |
| Siponimod | 2 (1.2) |
Values are presented as number (%) or median (range) unless otherwise indicated.
SD, standard deviation; EDSS, Expanded Disability Status Scale.